ReviewJournal of thoracic disease2017
Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.
Review in Journal of thoracic disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 120 citations in OpenAlex.
- Prognostic Value of the Lung Immune Prognostic Index in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab: A Real-World Analysis Beyond PD-L1 Expression.Diagnostics (Basel, Switzerland) · 2026Article
- Macrophage-Mediated Cellular Communication Networks in Lung Squamous Cell Carcinoma and Adenocarcinoma Revealed by Single-Cell Sequencing.Mediators of inflammation · 2026Article
- Intron retention regulates STAT2 function and predicts immunotherapy response in lung cancer.bioRxiv : the preprint server for biology · 2025Article
- Characteristics of folic acid metabolism-related genes unveil prognosis and treatment strategy in lung adenocarcinoma.BMC pulmonary medicine · 2025Article
- Characterization of the xeno-GVHD response generated by advanced lung cancer patient peripheral blood mononuclear cells in NSG-SGM3 mice.Translational lung cancer research · 2025Article
- Integrin β4 Regulates Cell Migration of Lung Adenocarcinoma Through FAK Signaling.Molecular biotechnology · 2025Article
- Article
- Clinical characteristics and risk factors of late-stage lung adenocarcinoma patients with bacterial pulmonary infection and its relationship with cellular immune function.Frontiers in immunology · 2025Article
- DNA Methylation Panels for the Differentiation of Lung and Gastric Adenocarcinomas from Other Common Primary Adenocarcinomas.Cancers · 2024Article
- Arsenic trioxide suppresses lung adenocarcinoma stem cell stemness by inhibiting m6A modification to promote ferroptosis.American journal of cancer research · 2024Article
- Alveolar type I cells can give rise to KRAS-induced lung adenocarcinoma.Cell reports · 2023Article
- Construction of a prognostic model for lung adenocarcinoma based on heat shock protein-related genes and immune analysis.Cell stress & chaperones · 2023Article
- Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy.International journal of molecular sciences · 2023Article
- MLK4 promotes glucose metabolism in lung adenocarcinoma through CREB-mediated activation of phosphoenolpyruvate carboxykinase and is regulated by KLF5.Oncogenesis · 2023Article
- Establishment and validation of nomograms for predicting survival of lung invasive adenocarcinoma based on the level of pathological differentiation: a SEER cohort-based analysis.Translational cancer research · 2023Article
- Systematically analyzed molecular characteristics of lung adenocarcinoma using metabolism-related genes classification.Genetics and molecular biology · 2023Article
- The DDR-related gene signature with cell cycle checkpoint function predicts prognosis, immune activity, and chemoradiotherapy response in lung adenocarcinoma.Respiratory research · 2022Article
- Prognostic significance of PD-L1 expression and CD8Journal of thoracic disease · 2022Article
- CircMMD_007 promotes oncogenic effects in the progression of lung adenocarcinoma through microRNA-197-3p/protein tyrosine phosphatase non-receptor type 9 axis.Bioengineered · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although adenocarcinoma (ADC) is the most frequent lung cancer, its diagnosis is often late, when the local invasion is important and/or the metastases have already appeared. Therefore, the mortality at 5 years is still very high, ranging from 51% to 99%, depending on the stage. The implementation of different molecular techniques has allowed genomic studies even in relatively small histological samples such as obtained with non-invasive or minimally invasive techniques, facilitating a better phenotyping of lung ADC. Thus, current classification differentiates between preinvasive lesions (atypical adenomatous hyperplasia and in situ ADC), minimally invasive ADC (MIA) and invasive ADC. 'Field cancerization' is a concept that refers to progressive loco-regional changes occurring in tissues exposed to carcinogens, due to the interaction of the latter with a predisposing genetic background and an appropriate tissue microenvironment. Somatic genetic alterations, including mutations but also other changes, are necessary for oncogenesis, being especially frequent in lung ADC. Changes in the epidermal growth factor receptor (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.